

# Abstract 252P: Characterization of sexual dysfunction in women with lung cancer: up date of the CLARIFY project.



**Aylen Vanessa Ospina Serrano<sup>1</sup>**, Virginia Calvo<sup>1</sup>, Ana Collazo Lorduy<sup>1</sup>, Mariola Blanco<sup>1</sup>, Ivan Triana<sup>2</sup>, Constanza Maximiano<sup>1</sup>, Maria Torrente<sup>1</sup>, Consuelo Parejo<sup>1</sup>, Marta Martinez-Cutilla<sup>1</sup>, Mariano Provencio-Pulla<sup>1</sup>.  
<sup>1</sup>Medical Oncology department Hospital Universitario Puerta de Hierro. Majadahonda-Madrid, España.<sup>3</sup> ICCAL Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá/CO.

## Background

- There has been an increase in the diagnosis of lung cancer (LC) in women.
- Some reports have shown a high prevalence of cancer treatment-related sexual dysfunction (SD) in women with LC.
- Our aim was to describe SD in a cohort of Spanish women with LC.

## Methods

- Analytical observational study in women with LC included in the CLARIFY H2020 project at the Hospital Universitario Puerta de Hierro.
- October 2020 to March 2023.
- Assessment of clinical and demographic variables and sexual function.
- Spanish-language and gender-specific validated questionnaire.
- Descriptive and logistic regression analyses were conducted.


## Results

- CLARIFY project overall population: 383 patients.
- 36.8% (141) had lung cancer wich 45.4% (64) were women.

Table 1. Caratheristics of population

Characteristics of women with LC	%N 64
Mean Age	63 years (range 44-85)
Tumoral stage	
Early	53%(33)
Metastatic	47%(30)
Marital status	
Married	75%(48)
Separated/Divorced	14%(9)
Single	5%(3)
Educational level	
University	38% (24)
Intermediate	20% (13)
Basic	2% (1)
No education	40% (26)
Histological type	
Adenocarcinoma	73%(47)
Squamous Cell carcinoma	6%(4)
Small Cell	11%(7)
Other	10%(6)
Time from diagnosis	
≥ 5 years	26.6% (17)
2-4 years	60.9% (39)
<1 year	12.5% (7)
Global dissatisfaction with sexual performance according to treatment	
Immunotherapy	56%(9)
Chemotherapy	68%(11)
Chemo immunotherapy	50%(3)
Follow up	100%(6)
Targeted therapy	42%(8)
according to tumoral stage	
Early	65%(21)
Metastatic	30%(9)

- Sexual activity during last 4 weeks



- Severe dysfunction of most phases of sexual response in 34-60% of women.

Statistically significant associations :

- ✓ Age ≥65 years OR 2.18 p0.04 (95% CI 1.01-4.7) and female gender OR 3.62 p 0.03 (95% CI 1.55-8.5) with Sexual performance dissatisfaction.
- ✓ Female gender OR 3.45 p 0.004 ( 95% CI 1.48-8.03) and age ≥65 years OR 2.04 p 0.06 (95% CI 1.48-8.03) with severe orgasm disorder.

## Conclusions

- In our study, women with LC are at significant risk for sexual dysfunction.
- It is necessary to screen and diagnose SD and offer multidisciplinary support.

*The presenter author has no conflict of interests to declare.*



This poster is part of a project that has received funding from the European Union's Horizon 2020 Research and Innovation Programme under GA No 875160.